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Wernicke’s encephalopathy is an acute neurological disorder characterized by mental confusion, 
oculomotor dysfunction, and ataxia. It has been reported in individuals with alcohol dependence, 
hyperemesis gravidarum, and prolonged parenteral nutrition without vitamin supplementation. Here 
we present the case of a 13-year-old male patient with neuroblastoma and a history of poor oral 
intake and nausea for 3 months. After admission, he showed gait disturbances, nystagmus, and 
excessive dizziness; his mental state, however, indicated he was alert, which did not fit the classical 
triad of Wernicke’s encephalopathy. A diagnosis of Wernicke’s encephalopathy was made only after 
brain magnetic resonance imaging and serum thiamine level analyses were performed. The patient’s 
symptoms remained after 5 days of treatment with 100-mg thiamine once daily; thus, we increased 
the dosage to 500 mg 3 times daily, 1,500 mg per day. His symptoms then improved after 20 days of 
replacement therapy. This case report describes a pediatric patient who was promptly diagnosed with 
Wernicke’s encephalopathy, despite only 2 suspicious symptoms, and who completely recovered after 
high doses of thiamine were given intravenously.
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Case report





Wernicke's encephalopathy, first described in 1881 by Carl Wernicke, is an acute 
neuropsychiatric syndrome that requires emergency treatment to prevent death and 
neurologic morbidity caused by thiamine (vitamin B1) deficiency
1-3). The classical triad of 
Wernicke's encephalopathy includes encephalopathy, oculomotor dysfunction and gait 
ataxia4). It is generally associated with alcoholism, anorexia nervosa and hyperemesis 
gravidarum which in turn induces thiamine deficiency5). In addition, it is also known to 
be related to prolonged parenteral nutrition without vitamin supplementation in systemic 
malignancy5). 
Here we report a case of a 13-year-old boy who was diagnosed with Wernicke's en-
cephalopathy derived from prolonged malnutrition during treatment for a neuroblastoma. 
He was treated with thiamine of 100 mg daily, and then of higher dosage (i.e., 500 mg three 
times a day) after 5 days. He was completely recovered after intravenous injection of high-
dose thiamine.
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Case report
A 13-year-old boy was diagnosed with neuroblastoma 
stage IV two years previously with no evidence of brain 
metastasis on initial cerebrospinal fluid study, and he received 
treatment 6 times with chemotherapy, as well as auto peripheral 
blood stem cell transplantation (auto PBSCT), therapeutic 
metaiodobenzylguanidine for residual tumor, and unrelated 
PBSCT for tumor relapse. When he was discharged from the 
hospital after successful unrelated PBSCT, he experienced 
increased nausea and vomiting, and poor oral intake. He was 
subsequently admitted to receive intravenous amino acid 
resuscitation (Trophamine) and total parenteral nutrition (TPN). 
When he was admitted, jitteriness on bilateral upper extremities 
was observed for a brief time while he was receiving intravenous 
amino acid resuscitation and TPN therapy. Under the impression 
of Wernicke’s encephalopathy, intravenous thiamine replacement 
was done. Although his thiamine level came out to be normal 
(6.9 μg/dL; reference range: 2–7.2 μg/dL), we kept thiamine 
replacement therapy for one week since his oral intake was very 
poor. Then we changed intravenous thiamine replacement into 
oral replacement for one more month to prevent Wernicke's 
encephalopathy. Brain magnetic resonance imaging (MRI) was 
not performed since his thiamine level was within normal range 
then. Since he had no apparent neurological symptoms and his 
oral intake improved, we discontinued thiamine prophylaxis at 
discharge. The patient visited the outpatient clinic for reappearing 
nausea, vomiting and poor oral intake, and received TPN and 
intravenous amino acid resuscitation on a regular basis. None-
theless, his symptoms did not improve and his general weakness 
increased. He was readmitted 3 months later.
One review of system, the patient had poor oral intake with 
nausea and vomiting, and he had lost 13 kg over 2 months. His 
initial vital signs were stable and his mental status was alert. 
Our initial physical examination did not reveal any abnormal 
neurological signs. Laboratory tests showed pancytopenia and 
elevated liver enzymes (The white blood cell count, hemoglobin 
level, and platelet count were 2,960/μL, 8.4 g/dL, and 139,000/μL 
respectively. His level for aspartate aminotransferase and alanine 
aminotransferase was 62 IU/L and 69 IU/L correspondingly). 
There were no specific findings from a brain MRI that was 
carried out on the day of admission in order to exclude brain 
metastasis. The patient received TPN replacement therapy while 
trying to develop his oral intake. On hospital day 7, he started 
to complain about dizziness, ataxic gait, and bilateral jerky type 
multidirectional nystagmus, but his mental status was alert 
and he did not show sensory changes in his extremities. On the 
evaluation of dizziness, neurological evaluation and consultation 
to Otolaryngology Department was done. His dizziness was not 
associated with spinning sensation, and it was nontrue vertigo 
type. He had no ear fullness or tinnitus, and his ear drums and 
hearing function were all intact. On neurological examination, 
his cranial nerve function test or deep tendon reflex test showed 
no remarkable findings, and rapid alternating test and finger-
to-nose test also showed normal findings. On standing, he 
was slightly swaying to right side, but he had no unilateral 
motor power impairment. Consultation to the Ophthalmology 
Department was done, and there was no papilledema or diplopia 
on physical examination. His brain computed tomography 
was unremarkable. However, brain MRI showed hyperintense 
lesions in the bilateral medial thalami and periaqueductal gray 
matter was visible in T2-weighted and fluid-attenuated inversion 
recovery images, characteristic of Wernicke's encephalopathy 
(Fig. 1A). An electroencephalogram showed somewhat slow and 
disorganized background rhythms, which were compatible with 
mild degree of diffuse brain dysfunction.
Under the impression of Wernicke's encephalopathy, we started 
intravenous replacement of thiamine 100 mg daily. On treatment 
day 5, his symptoms improved slightly, but nystagmus and 
dizziness remained. We then increased the amount of thiamine 
Fig. 1. (A) Bilateral hyperintense lesions are noted in the medial thalami on T2-weighted images (arrows). (B) Improved 
lesions, but remnant lesions are seen in brain magnetic resonance images after 9 days of thiamine replacement. (C) 
After 2 months of thiamine replacement, brain magnetic resonance imaging revealed normal findings.
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replacement to 500 mg three times a day. Brain MRI at 9 days 
of thiamine replacement showed a slight improvement but the 
lesions remained (Fig. 1B). The patient's dizziness and nystagmus 
improved and disappeared upon treatment days 10 and 14, 
respectively. He was discharged with an oral thiamine supplement 
on treatment day 18. The patient's thiamine level was 1.5 μg/dL 
when he was first diagnosed with Wernicke's encephalopathy, 
but his thiamine level was over 9 μg/dL before he was discharged 
from the hospital.
His oral intake did not improve significantly after he was 
discharged, and he was readmitted to our hospital two more 
times for intravenous thiamine replacement although he did not 
complain of any symptoms related to Wernicke's encephalopathy. 
On that time, follow-up of brain MRI was performed, and the 
image was improving compared to the MRI when he was first 
diagnosed with Wernicke’s encephalopathy. His brain MRI after 
two months of thiamine replacement was normal (Fig. 1C).
Discussion
Wernicke’s encephalopathy is caused by thiamine deficiency 
primarily in alcoholics, and it can also occur in impaired nutri-
tional states including gastrointestinal disorders, hyperemesis 
gravidarum and malignant diseases5,6). Thiamine pyrophosphate 
is a cofactor of the pyruvate dehydrogenase complex, alpha-keto-
glutarate dehydrogenase, and transketolase. These enzymes play 
a key role in the regulation of glucose and energy metabolism in 
the brain. Therefore, when there is a shortage of thiamine, cells 
fail to meet their metabolic demands, and eventually it leads to 
metabolic acidosis, cell death, and external imbalance2,3,7). Brain 
tissue from patients with Wernicke’s encephalopathy shows 
selective damage to subcortical areas of the brain that include the 
thalamus and mammillary bodies8). Oxidative stress, glutamate-
mediated excitotoxicity and inflammation are major contributors 
to regional neurodegeneration in Wernicke’s encephalopathy2).
A previous study detected the clinical triad of ocular symptoms, 
ataxia, and mental confusion in only 16% of Wernicke’s ence-
phalopathy patients4,5). Another study reported that the classic 
clinical triad was present in only 0.4% cases at onset8). In our 
case, the patient showed dizziness, nystagmus and ataxia, 
but his mental status was alert until recovery. The relatively 
nonspecific nature of the clinical presentation may have delayed 
the diagnosis in many cases. Early signs and symptoms include 
loss of appetite, nausea, weakness, giddiness, diplopia, memory 
loss and difficulty in concentration. It is not until the later stage 
when the patient shows signs and symptoms of the classic 
triad, hallucination, and coma, yet early intervention with 
thiamine replacement is essential to reverse the symptoms of 
Wernicke’s encephalopathy5,9-11). Brain MRI is the most sensitive 
technique and is required for all patients in whom Wernicke’s 
encephalopathy is suspected. Medial thalami, mammillary bodies, 
tegmentum, periaqueductal region, and tectal plate are typical 
sites of abnormal MRI signals. The dorsal medulla, red nuclei, 
cranial nerve nuclei, cerebellum, corpus callosum, frontal and 
parietal cerebral cortex are less common sites of involvement 
although they are more frequently affected in nonalcoholic 
cases5,12). In our case, brain MRI revealed the involvement of 
bilateral medial thalami and periaqueductal gray matter.
Empiric thiamine replacement should be initiated as soon 
as Wernicke’s encephalopathy is suspected. Delayed treatment 
may increase the likelihood of morbidity or mortality7). Patients 
require IV administration of at least 100 mg of thiamine daily for 
several days in Wernicke’s encephalopathy10,13). However, in order 
to prevent permanent damage (i.e., Korsakoff syndrome), the 
British National Formulary and the Royal College of Physicians, 
London (Royal College of Physicians 2001) recommend the 
immediate treatment guideline for Wernicke’s encephalopathy in 
alcoholics14). Thiamine 500 mg IV three times daily for 2 to 3 days 
and 250 mg IV daily for the next 3 to 5 days are recommended 
as immediate treatment14). However, there is no fixed guideline 
for pediatric patient who was diagnosed with Wernicke’s 
encephalopathy. Dosage of 50–100 mg daily or 1.8-mg thiamine 
per 1,000 kcal has been suggested in pediatric patients, and 100 
mg of daily thiamine replacement is routinely recommended 
in pediatric patients11,13). Furthermore, although high dose of 
thiamine replacement has not been documented in pediatric 
patients, high dose of thiamine therapy has been reported in 
nonalcoholic adult patient15). In our case, symptoms remained 
after use of 100 mg of thiamine when our patient was diagnosed 
with Wernicke’s encephloapathy, so we increased the dose to 
500 mg three times daily although Wernicke’s encephalopathy 
was not alcohol induced. The patient was symptom-free after 1 
week of high-dose thiamine replacement therapy. We prescribed 
him with oral thiamine on his discharge for supplementation. 
Furthermore, we have readmitted our patient for thiamine 
treatment therapy two more times after his discharge. Although 
he did not manifest a classical triad other than poor oral intake 
and general weakness, immediate replacement of thiamine helped 
him to recover his general condition.
In this report, we presented a case report of Wernicke’s ence-
phalopathy associated with prolonged malnutrition due to 
malignancy in a child. Since early diagnosis and optimal dosing 
is needed for complete recovery, it is important to suspect 
Wernicke’s encephalopathy and replace thiamine actively 
although the initial symptoms may not be typical. Moreover, a 
high dose of thiamine (500 mg three times daily) should also be 
considered immediately in the pediatric patient with incomplete 
recovery from Wernicke’s encephalopathy.
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